Novel Antiviral Molecules against Ebola Virus Infection

Area of Science:

• Virology
• Immunology
• Drug Discovery

Background:

• Ebola virus (EBOV) causes hemorrhagic fever with high mortality.
• RNA viruses necessitate combined prevention and therapeutic strategies due to their variability and outbreak potential.

Purpose of the Study:

• To screen a chemical library for compounds that inhibit EBOV infection.
• To identify novel antiviral agents targeting viral protein interactions.

Main Methods:

• Screening of the 2P2I3D chemical library using a nanoluciferase-based protein complementation assay (NPCA).
• Assessing compound efficacy against EBOV and measles virus (MV) in cell culture.
• Investigating the mechanism of action, focusing on disruption of EBOV VP35IID interactions with PKR and PACT.

Main Results:

• Two compounds were isolated that disrupt the interaction between EBOV VP35IID and dsRNA-binding proteins PKR and PACT.
• These compounds inhibited EBOV and MV infections in cell culture, independent of interferon induction.
• The antiviral effect is proposed to stem from the restoration of PACT-driven intrinsic immunity.

Conclusions:

• The identified compounds show promise as broad-spectrum antivirals against negative-sense RNA viruses.
• PACT's high conservation across mammals supports further testing in diverse species.
• These findings suggest a novel therapeutic avenue for managing viral hemorrhagic fevers and other RNA virus infections.